Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of TIL plus interleukin-2 versus dacarbazine in metastatic melanoma
NL-OMON34085Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous tumor-infiltrating lymphocytes, aldesleukin, dacarbazine, cyclophosphamide and fludarabine in melanoma (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Feasibility of logistics and timing, Toxicity and 2 more. Started May 2011; status: active, not recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytesaldesleukindacarbazinecyclophosphamidefludarabine
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON34085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34085.